Adoption of Advanced Brain Tumor Imaging Platform

Imaging Biometrics Expands Market Presence with Adoption of Advanced Brain Tumor Imaging Platform by Leading Regional Healthcare System

Imaging Biometrics Limited (LSE: IBAI) announces that its wholly owned US subsidiary, Imaging Biometrics LLC ("IB"), has entered into an annual subscription agreement with a leading health system for IB's quantitative neuro-oncology imaging software including IB Neuro, IB Delta T1, and IB FTBx.

The healthcare organization is among the first in the region to provide access to IB's advanced quantitative MRI technologies, bringing objective, standardized imaging biomarkers to neuro-oncology care and supporting more informed clinical decision-making throughout the patient journey.

Unlike conventional imaging approaches that rely on subjective interpretation or labor-intensive workflows, Imaging Biometrics' software automatically generates standardized, quantitative imaging biomarkers from routine MRI exams. By transforming complex imaging data into objective measures of tumor biology, the platform helps clinicians make more confident, consistent, and informed treatment decisions.

"This implementation reflects the continued evolution of neuro-oncology toward objective, quantitative imaging biomarkers that can support more confident clinical decision-making. By standardizing the assessment of tumor physiology and treatment response, our platform helps address some of the most significant challenges in brain tumor management. We are encouraged by the growing adoption of these technologies as healthcare systems seek proven solutions that can improve both clinical workflows and patient care," said Michael Schmainda, CEO of IB.

Trevor Brown, Chief Executive Officer of Imaging Biometrics Limited, said: "This is the second major new installation this quarter, testament to our increasingly relevant software."